chartexchange

PTGX
Protagonist Therapeutics, Inc
stockNASDAQ

At CloseNov 18, 2026 3:59:51 PM EST
127.22USD+2.045%(+2.55)432,812
After-hoursNov 18, 2026 4:00:30 PM EST
127.16USD-0.047%(-0.06)
Loading…
Loading…
Healthcare
Biotechnology
HQ
Newark, CA, USA
Previous Close
$124.67
Beta
0.94
52-Week High
$160.81 2026-08-19
52-Week Low
$77.00 2026-02-23
SMA 50
$139.46
SMA 200
$119.71
Avg. Vol 10D
625,415
Avg. Vol 30D
673,277
Avg. Vol 90D
628,241
Relative Vol
0.64
53.45M
10,242,340
0.4100%
1,263
PTGX Profile

protagonist therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. protagonist's initial lead peptide product candidates, ptg-100 and ptg-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (ibd), consisting primarily of ulcerative colitis and crohn's disease. ptg-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. ptg-200, a first-in-class oral interleukin-23 receptor antagonist

PTGX Performance
PeriodPriceDateChangeBeta
1W134.862026-11-11-5.61%1.907
1M134.442026-10-19-5.31%1.100
3M157.342026-08-18-19.09%1.266
6M100.742026-05-18+26.36%0.930
1Y84.392025-11-18+50.85%0.942
2Y40.392024-11-18+215.18%—
5Y36.412021-11-18+249.63%0.971
PTGX Stock Summary

Protagonist Therapeutics, Inc (NASDAQ:PTGX) stock price today is $127.30, and today's volume is 432,812. PTGX is up 2.110% today. The 30 day average volume is 673,277. PTGX market cap is $8.31B with 65.27M shares outstanding.